AU2021253128A1 - Crystalline forms of a TYK2 inhibitor - Google Patents
Crystalline forms of a TYK2 inhibitor Download PDFInfo
- Publication number
- AU2021253128A1 AU2021253128A1 AU2021253128A AU2021253128A AU2021253128A1 AU 2021253128 A1 AU2021253128 A1 AU 2021253128A1 AU 2021253128 A AU2021253128 A AU 2021253128A AU 2021253128 A AU2021253128 A AU 2021253128A AU 2021253128 A1 AU2021253128 A1 AU 2021253128A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- crystalline form
- mixture
- hours
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005114.0A GB202005114D0 (en) | 2020-04-07 | 2020-04-07 | Crystalline Forms of a Pharmaceutical Compound |
| GB2005114.0 | 2020-04-07 | ||
| PCT/EP2021/058864 WO2021204762A1 (en) | 2020-04-07 | 2021-04-06 | Crystalline forms of a tyk2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021253128A1 true AU2021253128A1 (en) | 2022-08-25 |
Family
ID=70768933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021253128A Pending AU2021253128A1 (en) | 2020-04-07 | 2021-04-06 | Crystalline forms of a TYK2 inhibitor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12545652B2 (https=) |
| EP (1) | EP4132649A1 (https=) |
| JP (1) | JP7660135B2 (https=) |
| KR (1) | KR20220164751A (https=) |
| CN (1) | CN115515683B (https=) |
| AU (1) | AU2021253128A1 (https=) |
| BR (1) | BR112022016359A2 (https=) |
| CA (1) | CA3167172A1 (https=) |
| GB (1) | GB202005114D0 (https=) |
| IL (1) | IL296989A (https=) |
| MX (1) | MX2022011593A (https=) |
| WO (1) | WO2021204762A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
| WO2023183910A1 (en) * | 2022-03-25 | 2023-09-28 | Nimbus Lakshmi, Inc. | Solid forms of tyk2 inhibitors and methods of use |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794096A (fr) | 1972-08-07 | 1973-05-16 | Lepetit Spa | Oxazoles 2,4,5-trisubstitues et leur preparation |
| GB1497536A (en) | 1973-12-17 | 1978-01-12 | Lilly Industries Ltd | 2-acylaminooxazoles methods for their preparation and their use |
| JPH0753716B2 (ja) | 1986-07-02 | 1995-06-07 | 吉富製薬株式会社 | イミダゾ−ルカルボキサミド誘導体 |
| DE19653355A1 (de) | 1996-12-20 | 1998-06-25 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung |
| GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| IL153246A0 (en) | 2000-06-28 | 2003-07-06 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
| DE60128731T2 (de) | 2000-10-30 | 2008-02-07 | Janssen Pharmaceutica N.V. | Tripeptidylpeptidase-hemmer |
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| EP1684750B1 (en) | 2003-10-23 | 2010-04-28 | AB Science | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors |
| GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| JP5222561B2 (ja) | 2005-10-07 | 2013-06-26 | キッセイ薬品工業株式会社 | 含窒素芳香族複素環化合物およびそれを含有する医薬組成物 |
| ES2352320T3 (es) | 2006-05-12 | 2011-02-17 | Ab Science | Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol. |
| WO2008024980A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| JP5478488B2 (ja) | 2007-06-20 | 2014-04-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｊａｎｕｓキナーゼの阻害剤 |
| EP2278969B1 (en) | 2008-04-21 | 2013-02-13 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| EP2299816B1 (en) | 2008-06-18 | 2013-11-13 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| US8420695B2 (en) | 2008-07-09 | 2013-04-16 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2166006A1 (en) | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| US20130096104A1 (en) | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| EP2588105A1 (en) | 2010-07-01 | 2013-05-08 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| CN103987713A (zh) | 2011-10-12 | 2014-08-13 | 阵列生物制药公司 | 5,7-取代的咪唑并[1,2-c]嘧啶 |
| EP3040336B1 (en) | 2012-03-02 | 2020-04-08 | Sareum Limited | Compounds for use in treating tyk2 kinase mediated conditions |
| KR101202026B1 (ko) | 2012-07-03 | 2012-11-16 | 민호현 | 황토 석부작 제조 방법 |
| LT3495358T (lt) | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| MX369974B (es) * | 2013-09-03 | 2019-11-27 | Sareum Ltd | Compuestos farmaceuticos. |
| NO2721710T3 (https=) | 2014-08-21 | 2018-03-31 | ||
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| GB201816369D0 (en) * | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
-
2020
- 2020-04-07 GB GBGB2005114.0A patent/GB202005114D0/en not_active Ceased
-
2021
- 2021-04-06 CA CA3167172A patent/CA3167172A1/en active Pending
- 2021-04-06 CN CN202180025999.3A patent/CN115515683B/zh active Active
- 2021-04-06 KR KR1020227038120A patent/KR20220164751A/ko active Pending
- 2021-04-06 EP EP21717041.4A patent/EP4132649A1/en active Pending
- 2021-04-06 IL IL296989A patent/IL296989A/en unknown
- 2021-04-06 MX MX2022011593A patent/MX2022011593A/es unknown
- 2021-04-06 JP JP2022559959A patent/JP7660135B2/ja active Active
- 2021-04-06 AU AU2021253128A patent/AU2021253128A1/en active Pending
- 2021-04-06 WO PCT/EP2021/058864 patent/WO2021204762A1/en not_active Ceased
- 2021-04-06 BR BR112022016359A patent/BR112022016359A2/pt unknown
- 2021-04-06 US US17/905,183 patent/US12545652B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230159473A1 (en) | 2023-05-25 |
| BR112022016359A2 (pt) | 2022-10-04 |
| MX2022011593A (es) | 2022-10-18 |
| WO2021204762A1 (en) | 2021-10-14 |
| JP2023521631A (ja) | 2023-05-25 |
| US12545652B2 (en) | 2026-02-10 |
| CA3167172A1 (en) | 2021-10-14 |
| JP7660135B2 (ja) | 2025-04-10 |
| IL296989A (en) | 2022-12-01 |
| EP4132649A1 (en) | 2023-02-15 |
| CN115515683B (zh) | 2024-10-25 |
| KR20220164751A (ko) | 2022-12-13 |
| GB202005114D0 (en) | 2020-05-20 |
| CN115515683A (zh) | 2022-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11673870B2 (en) | Pharmaceutical compounds | |
| JP6239118B2 (ja) | 医薬化合物 | |
| US12545652B2 (en) | Crystalline forms of a TYK2 inhibitor | |
| AU2019359320B2 (en) | TYK2 kinase inhibitors | |
| RU2805932C2 (ru) | Фармацевтические соединения | |
| HK40048146A (en) | Tyk2 kinase inhibitors | |
| HK40048146B (en) | Tyk2 kinase inhibitors |